Zosano Pharma Files Voluntary Petition for Relief Under Chapter 11
02 Juin 2022 - 2:00PM
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage
biopharmaceutical company, today announced that on June 1, 2022 it
filed a voluntary petition for relief under chapter 11 of title 11
(“Chapter 11”) of the United States Bankruptcy Code (the
“Bankruptcy Code”) in the United States Bankruptcy Court for the
District of Delaware (the “Bankruptcy Court”), thereby commencing a
Chapter 11 case for the company.
Zosano continues to operate its business as a
“debtor-in-possession” under the jurisdiction of the Bankruptcy
Court and in accordance with the applicable provisions of the
Bankruptcy Code and orders of the Bankruptcy Court. Zosano is
seeking approval of a variety of “first day” motions containing
customary relief intended to enable the company to continue its
ordinary course operations and to facilitate an orderly wind down
of its operations. The company intends to sell substantially all of
its assets during the bankruptcy case.
Additional information about the Chapter 11
case, including access to Bankruptcy Court documents, is available
online at http://www.kccllc.net/ZosanoPharma, a website
administered by KCC, a third-party bankruptcy claims and noticing
agent.
Forward-Looking StatementsThis press release
contains forward-looking statements. All statements other than
statements of historical facts contained herein are forward-looking
statements reflecting the current beliefs and expectations of
management made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995, including, but
not limited to, statements regarding the potential outcome of any
Chapter 11 filing or “first day” motions, its ability to complete
an orderly wind down of its operations, the ability to sell its
assets during the bankruptcy case and other future events and
expectations described in this press release. Readers are urged to
consider statements that include the words “may,” “will,” “would,”
“could,” “should,” “might,” “believes,” “estimates,” “projects,”
“potential,” “expects,” “plans,” “anticipates,” “intends,”
“continues,” “forecast,” “designed,” “scheduled,” “goal,”
“approximately” or the negative of those words or other comparable
words to be uncertain and forward-looking. These statements are
subject to risks and uncertainties that are difficult to predict,
and actual outcomes may differ materially. Although Zosano believes
that the expectations reflected in these forward-looking statements
are reasonable, Zosano cannot in any way guarantee that the future
results, level of activity, performance or events and circumstances
reflected in forward-looking statements will be achieved or occur.
All forward-looking statements are based on information currently
available to Zosano and Zosano assumes no obligation to update any
such forward-looking statements.
Zosano Contacts:Christine MatthewsChief
Financial Officer510-745-1200
Zosano PR:Sylvia Wheeler or Alexandra
Santosswheeler@wheelhouselsa.com or asantos@wheelhouselsa.com
Zosano Pharma (NASDAQ:ZSAN)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
Zosano Pharma (NASDAQ:ZSAN)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025